Filtered By:
Condition: Arrhythmia
Drug: Warfarin

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 353 results found since Jan 2013.

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion.
Abstract Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real "epidemic phenomenon". Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alte...
Source: Medicina (Kaunas) - September 29, 2019 Category: Universities & Medical Training Authors: Coppola G, Manno G, Mignano A, Luparelli M, Zarcone A, Novo G, Corrado E Tags: Medicina (Kaunas) Source Type: research

87 Evolution of Atrial Fibrillation
ConclusionThere has been a significant increase in primary prevention practices for AF and this is reflected in the number of stroke patients presenting with known AF on a NOAC, however more needs to be done as there are still patients who have AF that are not being anticoagulated in the community.
Source: Age and Ageing - September 16, 2019 Category: Geriatrics Source Type: research

Left atrial appendage closure: a therapy uniquely suited for specific populations of patients with atrial fibrillation
This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - September 12, 2019 Category: Cardiology Authors: Eric Black ‐Maier, Jonathan P. Piccini, Christopher Granger Tags: POINT OF VIEW Source Type: research

Determinants of Antithrombotic Treatment for Atrial Fibrillation in Octogenarians: Results of the OCTOFA Study
ConclusionsMost private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillation patients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
Source: Clinical Drug Investigation - June 9, 2019 Category: Drugs & Pharmacology Source Type: research

Protocol of a clinical trial study involving educational intervention in patients treated with warfarin
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. Oral anticoagulation is an effective strategy for primary and secondary prevention of stroke in patients with AF. Warfarin is an oral anticoagulant widely prescribed and, despite its benefits, the achievement of the goals of drug therapy depends on patient involvement, among other factors. Educational interventions can contribute for effectiveness and safety of oral anticoagulation therapy. We sought to describe the protocol of a clinical trial designed to evaluate the effect of a patient-centered educational strategy focused on low-i...
Source: Medicine - May 1, 2019 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation
Atrial fibrillation (AF) is one of the most common arrhythmias in elderly people. The risk of thromboembolic stroke is increased in AF patients, especially those with diabetes. Anticoagulant therapy, such as w...
Source: Cardiovascular Diabetology - January 28, 2019 Category: Cardiology Authors: Sho-ichi Yamagishi Tags: Commentary Source Type: research

A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation.
CONCLUSIONS: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs. PMID: 30380959 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 2, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation.
Authors: Székely O, Miyazawa K, Lip GYH Abstract INTRODUCTION: Atrial fibrillation (AF) is associated with high morbidity and mortality rates due to thromboembolic complications, and anticoagulation is central to the management of this common arrhythmia to prevent acute thromboembolic events. The traditional anticoagulants: heparin, fondaparinux, and vitamin K antagonists (VKA, e.g. warfarin, acenocoumarol or phenprocoumin) have long served as pharmacotherapy for ischemic stroke prophylaxis. Areas covered: In this review article, the authors provide an overview on current and emerging pharmacotherapy for ischemic ...
Source: Expert Opinion on Pharmacotherapy - October 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Dabigatran - the First Approved DTI for SPAF.
Authors: Trailokya A, Hiremath JS Abstract Atrial fibrillation (AF) is commonly occurring arrhythmia in clinical practice. AF is easy to recognize but difficult to treat. Stroke is the most devastating complication of AF and is associated with a huge disease burden on the society. Effective stroke prevention is a priority for patients with AF. Two-thirds of strokes due to AF are preventable with suitable anticoagulant therapy. VKA like warfarin, acenocoumarol remains the gold standard for stroke prevention in AF (SPAF). However, it is associated with numerous limitations such as a high risk of drug-drug, drug-food ...
Source: Journal of the Association of Physicians of India - October 25, 2018 Category: General Medicine Tags: J Assoc Physicians India Source Type: research

Variation in the Use of Warfarin and Direct Oral Anticoagulants in Atrial Fibrillation and Associated Cost Implications
Atrial fibrillation is the most common arrhythmia in the United States and affects between 2.7 million and 6.1 million adults in the United States, with a lifetime risk of up to 1 in 4 adults over age 40 and a prevalence that is projected to double over the next 25 years.1,2 Though warfarin has long been the cornerstone of therapy to reduce the risk of stroke, several new direct oral anticoagulants (DOACs) have recently become available, beginning with FDA approval of dabigatran in October 2010, and followed by rivaroxaban in 2011, apixaban in 2014, and most recently edoxaban in 2015.
Source: The American Journal of Medicine - October 3, 2018 Category: General Medicine Authors: Benjamin A. Rodwin, Joseph A. Salami, Erica S. Spatz, Javier Valero-Elizondo, Salim S. Virani, Ron Blankstein, Michael J. Blaha, Khurram Nasir, Nihar R. Desai Tags: Clinical Research Study Source Type: research

Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Publication date: September 2018Source: IJC Heart & Vasculature, Volume 20Author(s): Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann ChenAbstractAtrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X...
Source: IJC Heart and Vasculature - September 1, 2018 Category: Cardiology Source Type: research

Sex Differences in Atrial Fibrillation —Update on Risk Assessment, Treatment, and Long-Term Risk
AbstractPurpose of reviewAtrial fibrillation (AF) is a growing health problem worldwide. While the disease plagues both men and women, this arrhythmia does not affect both sexes equally. Women are more likely to have major adverse outcomes such as stroke and its sequela; however, recent data on stroke prevention show improving outcomes. The purpose of this review of the recent literature is to summarize important updates on risk scores and management of patients with AF.Recent findingsIt has been well known that women have a higher risk of strokes than men when untreated or when treated with warfarin. Current risk scores e...
Source: Current Treatment Options in Cardiovascular Medicine - August 27, 2018 Category: Cardiology Source Type: research

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.
Authors: Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, Hendriks J, Hespe CM, Hung J, Kalman JM, Sanders P, Worthington J, Yan T, Zwar NA Abstract INTRODUCTION: Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are continually evolving and care for patients requires confidence in integrating these new developments into practice. These clinical practice guidelines will assist Australian practitioners in the diagnosis and management of adult ...
Source: Medical Journal of Australia - August 3, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Uninterrupted NOAC therapy in patients undergoing catheter ablation of atrial fibrillation: “Dual anticoagulant therapy” ready for primetime or systematic overtreatment?
Catheter ablation of atrial fibrillation (AF) appears as a very promising technique to reduce arrhythmia episodes in patients with AF [1]. The major adverse events of such procedures are bleeding complications and stroke. Therefore, several studies were performed to assess efficacy and safety of different oral anticoagulants like warfarin (VKA) and non-VKA oral anticoagulants (NOAC). NOAC therapy has been explored in patients with chronic AF and in patients undergoing antiarrhythmic procedures [2, 3].
Source: International Journal of Cardiology - June 13, 2018 Category: Cardiology Authors: Andreas Goette Tags: Editorial Source Type: research